Falmouth, ME, United States of America

Mahalakshmi Yerramilli

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Mahalakshmi Yerramilli: Innovator in Renal and Periodontal Disease Detection

Introduction

Mahalakshmi Yerramilli is a prominent inventor based in Falmouth, ME (US). She has made significant contributions to the fields of renal and periodontal disease detection. With a total of 9 patents, her work has advanced the understanding and diagnosis of these critical health issues.

Latest Patents

Yerramilli's latest patents include innovative methods and compositions for the detection and diagnosis of renal disease and periodontal disease. One notable patent provides compositions and methods for identifying renal disease in mammals. This invention highlights biomarkers such as differential levels of inosine metabolite and various proteins, including apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, kininogen, and Inter-Alpha Inhibitor H4 (ITIH4). These biomarkers are crucial for diagnosing renal disease and are detailed in her disclosures.

Career Highlights

Mahalakshmi Yerramilli is currently associated with IDEXX Laboratories, Inc., where she continues to innovate in her field. Her work has not only contributed to scientific knowledge but has also had practical applications in medical diagnostics.

Collaborations

Some of her notable coworkers include Murthy V S N Yerramilli and Michael Randolph Atkinson. Their collaborative efforts have further enhanced the research and development of diagnostic methods in the medical field.

Conclusion

Mahalakshmi Yerramilli's contributions to the detection and diagnosis of renal and periodontal diseases exemplify her dedication to innovation in healthcare. Her patents and ongoing work at IDEXX Laboratories, Inc. continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…